
Biogen Idec Inc.'s diagnostic test that may help determine the risk of developing a rare brain infection in patients using multiple sclerosis drug Tysabri has received marketing approval in Europe.
Tysabri, sold with Elan Corp, is a highly effective treatment for the debilitating disease, but it has been linked in a small number of patients to progressive multifocal leukoencephalopathy, or PML. Global sales rose 16% to $ 1.2 billion last year, although growth has been lower than originally expected in recent years because of the risks of the infection....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1905